Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,721.20
(
-0.31%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.45
(
3.63%
)
Bitcoin
70,121.47
(
-1.57%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 80846

Tuesday, 07/14/2009 9:45:03 PM

Tuesday, July 14, 2009 9:45:03 PM

Post# of 257257

What biotech company would pay hundreds of millions of dollars to pay for trials just to get five years exclusivity. If the innovator only gets five years exclusivity innovation would die.

That’s total BS, drbio. If a new biotech drug is innovative, it can presumably be patented. A patent affords protection from competition irrespective of the data-exclusivity period in FoB legislation.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now